2,4-dichloro-5-fluoro-6-(4-methylpiperazin-1-yl)pyrimidine | 1431864-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2,4-dichloro-5-fluoro-6-(4-methylpiperazin-1-yl)pyrimidine
• 英文别名: 2,4-Dichloro-5-fluoro-6-(4-methylpiperazin-1-yl)pyrimidine
• CAS: 1431864-28-6
• 化学式: C₉H₁₁Cl₂FN₄
• 分子量: 265.118
• InChiKey: CAIZHKRXWPXGDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-5-fluoro-6-(4-methylpiperazin-1-yl)pyrimidine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 生成 (S)-5-fluoro-N4-(1-(5-fluoropyridin-2-yl)ethyl)-N2-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Discovery of novel Jak2–Stat pathway inhibitors with extended residence time on target

  摘要：

  The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncology. In this Letter, we communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivatives. The rationale, synthesis and biological evaluation of these derivatives are reported. Two lead analogs from this series, 6 and 9, displayed prolonged residence time on Jak2, at enzymatic level. Although 6 and 9 exhibited moderate selectivity in a selected kinase panel, we chose to test these inhibitors in vivo as a consequence to their long residence time. However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.111
• 作为产物：
  描述：

  N-甲基哌嗪 、 2,4,6-三氯-5-氟嘧啶 以 乙醇 为溶剂， 生成 2,4-dichloro-5-fluoro-6-(4-methylpiperazin-1-yl)pyrimidine
  参考文献：
  名称：

  Discovery of novel Jak2–Stat pathway inhibitors with extended residence time on target

  摘要：

  The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncology. In this Letter, we communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivatives. The rationale, synthesis and biological evaluation of these derivatives are reported. Two lead analogs from this series, 6 and 9, displayed prolonged residence time on Jak2, at enzymatic level. Although 6 and 9 exhibited moderate selectivity in a selected kinase panel, we chose to test these inhibitors in vivo as a consequence to their long residence time. However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.111

文献信息

• Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure–Activity Relationships, Lead Optimization, and Chronic In Vivo Efficacy
  作者：Dean P. Phillips、Wenqi Gao、Yang Yang、Guobao Zhang、Isabelle K. Lerario、Thomas L. Lau、Jiqing Jiang、Xia Wang、Deborah G. Nguyen、B. Ganesh Bhat、Carol Trotter、Heather Sullivan、Gustav Welzel、Jannine Landry、Yali Chen、Sean B. Joseph、Chun Li、W. Perry Gordon、Wendy Richmond、Kevin Johnson、Angela Bretz、Badry Bursulaya、Shifeng Pan、Peter McNamara、H. Martin Seidel

  DOI：10.1021/jm401731q

  日期：2014.4.24

  Activation of the G-protein coupled receptor (GPCR) Takeda G-protein receptor 5 (TGR5), also known as G-protein bile acid receptor 1 (GPBAR1), has been shown to play a key role in pathways associated with diabetes, metabolic syndrome, and autoimmune disease. Nipecotamide 5 was identified as an attractive starting point after a high-throughput screen (HTS) for receptor agonists. A comprehensive hit-to-lead effort culminated in the discovery of 45h as a potent, selective, and bioavailable TGR5 agonist to test in preclinical metabolic disease models. In genetically obese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chronic dosing.
• Discovery of novel Jak2–Stat pathway inhibitors with extended residence time on target
  作者：Huiping Guan、Michelle L. Lamb、Bo Peng、Shan Huang、Nancy DeGrace、Jon Read、Syeed Hussain、Jiaquan Wu、Caroline Rivard、Marat Alimzhanov、Geraldine Bebernitz、Kirsten Bell、Minwei Ye、Michael Zinda、Stephanos Ioannidis

  DOI：10.1016/j.bmcl.2013.02.111

  日期：2013.5

  The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncology. In this Letter, we communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivatives. The rationale, synthesis and biological evaluation of these derivatives are reported. Two lead analogs from this series, 6 and 9, displayed prolonged residence time on Jak2, at enzymatic level. Although 6 and 9 exhibited moderate selectivity in a selected kinase panel, we chose to test these inhibitors in vivo as a consequence to their long residence time. However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting. (c) 2013 Elsevier Ltd. All rights reserved.